According to a report from CNN Money, Inovio Pharmaceuticals, Inc. (NASDAQ:INO) leapt 25.12 percent to $8.12 after the company announced a $700 million deal with MedImmune, AstraZenecaâ€™s R&D arm. MedImmune will gain the exclusive rights to INO-3312 and INO-3113, two pipeline therapies that aim to treat specific strains of HPV.
MedImmune will pay Inovio $27.5 million up front for the rights, but will pay a total of $700 million over future milestone payments. Analysts all agree that now is a good time to pick up shares of Inovio, Inc.
20:05 Headphone deal of the day: Klipsch Reference On-Ear Premium headphone for $30
11:32 Brexit: EU negotiator says 'time's short' for reaching deal11
09:13 Rouhani says Iran will not let Trump rip up nuclear deal13
22:35 Bryce Harper's request for record $400 million deal too much for Nationals: report2